This article is more than 5 years old. Information may no longer be current.

FDA advisory committee recommends approval of besifloxacin drop for bacterial conjunctivitis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ROCHESTER, N.Y. — The U.S. Food and Drug Administration Dermatologic and Ophthalmic Drugs Advisory Committee has recommended approval of a 6% formulation of besifloxacin ophthalmic suspension for treating bacterial conjunctivitis, according to a press release from Bausch & Lomb, the developer of the drug.

"We are encouraged by this morning's committee discussion and vote, and look forward to continue working with the FDA to gain final approval," Flemming Ornskov, MD, MPH, corporate vice president and global president of pharmaceuticals for Bausch & Lomb, said in the release. "Our intent remains to bring this innovative product to market, beginning in the U.S., in 2009."

Although the FDA is not required to adhere to the panel's recommendations, in most cases it does.